Eventide Asset Management, LLC Nektar Therapeutics Transaction History
Eventide Asset Management, LLC
- $5.67 Billion
- Q3 2024
A detailed history of Eventide Asset Management, LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Eventide Asset Management, LLC holds 9,400,000 shares of NKTR stock, worth $8.55 Million. This represents 0.22% of its overall portfolio holdings.
Number of Shares
9,400,000
Previous 7,529,096
24.85%
Holding current value
$8.55 Million
Previous $9.34 Million
30.89%
% of portfolio
0.22%
Previous 0.16%
Shares
2 transactions
Others Institutions Holding NKTR
# of Institutions
145Shares Held
139MCall Options Held
32.6KPut Options Held
14.1K-
Deep Track Capital, LP Greenwich, CT15.9MShares$14.5 Million0.76% of portfolio
-
Black Rock Inc. New York, NY15.2MShares$13.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$11.9 Million0.0% of portfolio
-
Samlyn Capital, LLC New York, NY9.2MShares$8.37 Million0.19% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il6.95MShares$6.33 Million0.0% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $171M
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...